


Elder Pharmaceuticals Ltd.

Registered Office : 'Elder House', C -9, Dalia Industrial Estate, Off Veera Desai Rd, Andheri (W), Mumbai 400053

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2010

(₹ in Lakhs)

Sr. No.	Particulars	3 months ended 31/12/2010 Unaudited	Corresponding 3 months ended in the previous year 31/12/2009 Unaudited	Year to date figures for current period ended 31/12/2010 Unaudited	Year to date figures for the previous year ended 31/12/2009 Unaudited	Previous accounting year ended 31/03/2010 Audited
1.	(a) Net Sales / Income from Operations	25154.27	17998.95	65648.85	51228.10	72089.84
	(b) Other Operating Income	19.56	18.53	62.77	34.54	70.31
	Total Income (a+b)	25173.83	18017.48	65711.62	51262.64	72160.15
2.	Expenditure % of Consumption	51.83	46.90	49.62	47.24	48.19
	(a) Increase(-) / Decrease (+) In Stocks In Trade & Work In Process	-1717.42	-230.25	-1499.97	-2682.84	-5152.93
	(b) Consumption Of Raw Materials	2654.37	2898.14	8328.77	8263.33	10253.94
	(c) Purchase Of Traded Goods	12100.92	5772.79	25747.29	18620.96	29638.96
	(d) Employees Cost	2809.08	2463.76	8361.70	7429.89	9664.74
	(e) Depreciation	801.84	353.45	2054.28	1048.32	1719.23
	(f) Other Expenditure	4826.05	3464.22	12307.65	10122.24	15514.87
	(g) Total	21474.84	14722.11	55299.72	42801.90	61638.81
3.	Profit From Operations Before Other Income, interest & Exceptional Items (1-2)	3698.99	3295.37	10411.90	8460.74	10521.34
4.	Other Income	184.99	209.24	510.22	481.73	857.76
5.	Profit before Interest & Exceptional Items (3+4)	3883.98	3504.61	10922.12	8942.47	11379.10
6.	Interest	1759.45	1523.52	4668.38	3949.71	5302.08
7.	Profit After Interest But Before Exceptional Items (5-6)	2124.53	1981.09	6253.74	4992.76	6077.02
8.	Exceptional Items	126.16	143.73	424.22	348.29	426.00
9.	Profit From Ordinary Activities Before Tax (7+8)	1998.37	1837.36	5829.52	4644.47	5651.02
10.	Tax Expenses	425.00	300.00	1300.00	800.00	928.83
11.	Net Profit From Ordinary Activities After Tax (9-10)	1573.37	1537.36	4529.52	3844.47	4722.19
12.	Extraordinary Item (Net Of Tax Exp. Rs.)	---	---	---	---	---
13.	Net Profit for the Period (11-12)	1573.37	1537.36	4529.52	3844.47	4722.19
14.	Share Of Minority Interest In(profit)/loss	9.80	0.00	89.54	0.00	227.94
15.	Net Profit For The Period After Minority Interest	1583.17	1537.36	4619.06	3844.47	4950.13
16.	Paid Up Equity Share Capital (face Value Of Shares Rs. 10/-)	2053.69	1885.74	2053.69	1885.74	1885.74
17.	Reserve Excluding Revaluation Reserves As Per Balance Sheet Of Previous Accounting Year	---	---	---	---	46159.40
18.	Earnings Per Share (Eps.)					
	(a) Basic Eps Before Extraordinary Items For The Period, For The Year To Date & For The Previous Year (not To Be Annualized)	8.40	8.91	24.49	22.23	26.25
	(b) Diluted Eps After Extraordinary Items For The Period, For The Year To Date & For The Previous Year (not To Be Annualized)	7.71	8.91	23.74	22.23	29.37
19.	Public Shareholding:					
	- Number Of Shares	12821128	11215678	12821128	11215678	11215678
	- Percentage Of Shareholding	62.43	59.47	62.43	59.47	59.48
20.	Promoters & Promoter Group Shareholding					
	(a) Pledged/encumbered					
	- Number Of Shares	5121570	5212185	5121570	5212185	4534279
	- Percentage Of Shares(as A % Of The Total Share Holding Of Promoter & Promoter Group)	66.38	68.21	66.38	68.21	59.34
	- Percentage Of Shares (as A % Of Total Share Capital Of The Company)	24.94	27.64	24.94	27.64	24.04
	B) Non - Encumbered					
	- Number Of Shares	2594238	2429623	2594238	2429623	3107529
	- Percentage Of Shares(as A % Of The Total Share Holding Of Promoter & Promoter Group)	33.63	31.79	33.63	31.79	40.66
	- Percentage Of Shares (as A % Of Total Share Capital of the Company)	12.62	12.88	12.62	12.88	16.48

Key standalone financial information (as per clause 41 of listing Agreement)

1.	Turnover	20971.54	18017.48	60521.62	51262.64	70279.14
2.	Profit before tax	2231.50	1837.36	6607.89	4644.47	6467.95
3.	Profit after tax	1806.50	1537.36	5307.89	3844.47	5539.12

- NOTES:**
- The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 07th February, 2011
 - The statutory Auditors have carried out a limited review of the unaudited (provisional) financial results for the quarter ended 31st December, 2010.
 - Pursuant to the provisions of AS-17 on Segment reporting the Company has only one reportable segment, viz. Pharmaceuticals. Accordingly, segmental information is not required to be given.
 - The Company through its Wholly Owned Subsidiary in Dubai, has acquired the entire share capital of NeutraHealth PLC, U. K. under the Scheme of Arrangement route. The said Scheme has become effective from 16th November 2010.
 - During the quarter under review the Company issued and allotted 1188 units of Rs.10.00 lacs each of Secured Redeemable Non-Convertible Debentures (NCDs) aggregating Rs.118.80 crores. The said NCDs are listed on the WDM segment of the National Stock Exchange of India Ltd.
 - Exceptional item of Rs.124.95 lacs pertains to exchange loss on quarterly installment of ECB repayment.
 - Provision for Tax includes current tax. Deferred tax will be provided at the year end.
 - Investor complaints: Pending at the beginning of the quarter - Nil. Received during the quarter -11. Pending at the end of the quarter - Nil
 - Previous year's figures have been regrouped/re-arranged wherever necessary.

Place: Mumbai
Date : 07th February, 2011

For **ELDER PHARMACEUTICALS LIMITED**
J. Saxena
Managing Director

Sentinel